Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Nat Cancer Center. 2022;2:1–9.

Article  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer j clin. 2021;71:209–49.

Google Scholar 

Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecologic oncol. 2013;130:493–8.

Article  Google Scholar 

Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic oncol. 2003;90:390–6.

Article  Google Scholar 

Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecologic oncol. 2012;125:483–92.

Article  Google Scholar 

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane database system rev. 2011;2011:Cd007565.

Google Scholar 

Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecologic oncol. 2008;108:271–5.

Article  Google Scholar 

Bacalbasa N, Balescu I, Dima S, Herlea V, David L, Brasoveanu V, et al. Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management. Anticancer res. 2015;35:2315–20.

PubMed  Google Scholar 

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249-57.

Milam MR, Tao X, Coleman RL, Harrell R, Bassett R, Dos Reis R, et al. Neoadjuvant chemotherapy is associated with pro-longed primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:66–71.

Article  PubMed  Google Scholar 

Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic oncol. 2006;103:1070–6.

Article  CAS  Google Scholar 

Gao Y, Li Y, Zhang C, Han J, Liang H, Zhang K, et al. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study. J ovarian res. 2019;12:85.

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Jiao X, Gao Q. Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. Drug discovery today. 2020;25:1232–8.

Article  CAS  PubMed  Google Scholar 

Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J clin oncol: official j Am Soc Clin Oncol. 2015;33:937–43.

Article  Google Scholar 

Mataga V, Matković V. Role of neoadjuvant chemotherapy in the advanced ovarian cancer. Lijecnicki vjesnik. 2013;135:21–6.

PubMed  Google Scholar 

Karlsen MA, Fagö-Olsen C, Høgdall E, Schnack TH, Christensen IJ, Nedergaard L, et al. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study. Tumour biol: the j Int Soc Oncodevelopment Biol Med. 2016;37:12619–26.

Article  CAS  Google Scholar 

Narasimhulu DM, McGree ME, Weaver AL, Jatoi A, LeBrasseur NK, Glaser GE, et al. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Gynecologic oncol. 2020;158:646–52.

Article  CAS  Google Scholar 

Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532–40.

Article  CAS  PubMed  Google Scholar 

Brun JL, Rouzier R, Uzan S, Daraï E. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecologic oncol. 2008;110:354–9.

Article  Google Scholar 

Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD, et al. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am j obstetr gynecol. 2013;209:462.e1-.e11.

Matsuhashi T, Takeshita T, Yamamoto A, Kawase R, Yamada T, Kurose K, et al. Serum CA125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer. J Nippon Med School = Nippon Ika Daigaku zasshi. 2017;84:170–6.

Article  PubMed  Google Scholar 

Pradjatmo H, Pradjatmo H. Impact of Preoperative Serum Levels of CA125 on Epithelial Ovarian Cancer Survival. Asian Pacif j cancer prevent: APJCP. 2016;17:1881–6.

Article  Google Scholar 

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA 125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic oncol. 2014;134:455–61.

Article  CAS  Google Scholar 

Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic oncol. 2009;112:40–6.

Article  CAS  Google Scholar 

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecologic oncol. 2017;145:27–31.

Article  Google Scholar 

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J clin oncol: official j Am Soc Clin Oncol. 2002;20:1248–59.

Article  Google Scholar 

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecologic oncol. 2006;103:559–64.

Article  CAS  Google Scholar 

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecologic oncol. 2006;103:1083–90.

Article  Google Scholar 

Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J surg oncol. 2010;101:13–7.

Article  CAS  PubMed  Google Scholar 

Pergialiotis V, Karampetsou N, Bellos I, Thomakos N, Daskalakis G. The Diagnostic Accuracy of Human Epididymis Factor 4 for the Prediction of Optimal Debulking in Patients With Ovarian Cancer: A Meta-Analysis of Observational Studies. Int J Gynecol Cancer. 2018;28:1471–7.

Article  PubMed  Google Scholar 

Rutten MJ, van de Vrie R, Bruining A, Spijkerboer AM, Mol BW, Kenter GG, et al. Predicting surgical outcome in patients with International Federation of Gynecology and Obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models. Int J Gynecol Cancer. 2015;25:407–15.

Article  PubMed  Google Scholar 

Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert rev molecular diagnostics. 2017;17:577–91.

Article  CAS  Google Scholar 

Mahdi H, Maurer KA, Nutter B, Rose PG. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy. Int J Gynecol Cancer. 2015;25:823–9.

Article  PubMed  Google Scholar 

Scaletta G, Plotti F, Luvero D, Capriglione S, Montera R, Miranda A, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert rev anticancer therapy. 2017;17:827–39.

Article  CAS  Google Scholar 

Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecologic oncol. 2013;128:579–83.

Article  CAS  Google Scholar 

Tang Z, Chang X, Ye X, Li Y, Cheng H, Cui H. Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. Chin j cancer res. 2015;27:309–17.

CAS  PubMed  PubMed Central  Google Scholar 

Gu Y, Qin M, Jin Y, Zuo J, Li N, Bian C, et al. A Prediction Model for Optimal Primary Debulking Surgery Based on Preoperative Computed Tomography Scans and Clinical Factors in Patients With Advanced Ovarian Cancer: A Multicenter Retrospective Cohort Study. Front oncol. 2020;10:611617.

Article  PubMed  Google Scholar 

Kim HJ, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, et al. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. Taiwanese j obstetr gynecol. 2014;53:343–7.

Article  Google Scholar 

Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J clin oncol: official j Am Soc Clin Oncol. 1993;11:166–72.

Article  CAS  Google Scholar 

Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecologic oncol. 2005;96:301–6.

Article  Google Scholar 

Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Nat Comprehensive Cancer Network: JNCCN. 2022;20:972–80.

Article  Google Scholar 

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143:3–15.

Article  PubMed  PubMed Central  Google Scholar 

Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann surg oncol. 2006;13:1156–61.